NCT04403698COMPLETEDanonymous

The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover

Sponsor

Source record

University Hospital, Ghent

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Alendronate Effervescent Oral Tablet

Indication / condition

AI-normalized

Erosive Osteoarthritis

Intervention

Source record

Alendronate Effervescent Oral Tablet

Related intelligence directories

Indication directory: Erosive Osteoarthritis Modality directory: monoclonal antibody Target directory: Alendronate Effervescent Oral Tablet

Source & freshness

Source record

NCT ID

NCT04403698

Original source

ClinicalTrials.gov

Source last updated

Dec 13, 2024

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04403698

Title

The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover

Sponsor

University Hospital, Ghent

Status

COMPLETED

Phase

PHASE2

Condition raw

Erosive Osteoarthritis

Condition normalized

Erosive Osteoarthritis

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Alendronate Effervescent Oral Tablet

Target normalized

Alendronate Effervescent Oral Tablet

Interventions

Alendronate Effervescent Oral Tablet

Public preview

Source record

It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect), after discontinuation of denosumab treatment in a non-osteoporotic population.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT04403698

Status

COMPLETED

Phase

PHASE2

Sponsor

University Hospital, Ghent

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDec 13, 2024

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04403698

Indication

Erosive Osteoarthritis

Modality

monoclonal antibody

Target

Alendronate Effervescent Oral Tablet

Intervention

Alendronate Effervescent Oral Tablet

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.